PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 15 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Ether extract of S. bimaculata significantly alleviated liver damage and hepatocyte degeneration, lowering serum levels of ALT, AST, malondialdehyde, IL-1β, and TNF-α in mice [PMID:37418941].
Dichloromethane extracts and corymbiferin decreased fasting blood glucose, increased serum insulin, improved oral glucose tolerance, and lowered total cholesterol, LDL, and triglycerides in diabetic rats [PMID:24250711].
Swertiamarin attenuated NAFLD in fructose-fed mice, reducing serum glucose, triglycerides, uric acid, and ALT [PMID:31005808].
The compound aspterpenacid C exhibited moderate activity in inhibiting HIV-1 replication in vitro (EC50 = 1.35 μM) [PMID:28662527].
The compound aspterpenacid C exhibited moderate activity in inhibiting nitric oxide production in vitro (IC50 = 16.1 μM) [PMID:28662527].
Evidence summary
PubMed sources
- 1.PMID: 39166008 (2024) — Chrono-spatial reproductive phenology of Swertia bimaculata Hook.f. & Thomson ex C.B.Clarke reveals suitability as climate-changing bio-indicator along the Sikkim Himalayan altitude. · Heliyon
- 2.PMID: 37418941 (2023) — Swertia bimaculata moderated liver damage in mice by regulating intestine microbiota. · Ecotoxicology and environmental safety
- 3.PMID: 29607017 (2018) — Nectary tracks as pollinator manipulators: The pollination ecology of Swertia bimaculata (Gentianaceae). · Ecology and evolution
- 4.PMID: 24687743 (2014) — Xanthone glycosides from Swertia bimaculata with α-glucosidase inhibitory activity. · Planta medica
- 5.PMID: 28662527 (2017)